Breaking News Instant updates and real-time market news.

AVY

Avery Dennison

$127.53

8.97 (7.57%)

, IVZ

Invesco

$16.66

0.63 (3.93%)

09:55
10/23/19
10/23
09:55
10/23/19
09:55

Early notable gainers among liquid option names on October 23rd

Notable gainers among liquid option names this morning include Avery Dennison (AVY) $127.19 +8.71, Invesco (IVZ) $16.89 +0.86, Thermo Fisher (TMO) $294.63 +13.68, Alexion (ALXN) $104.00 +4.76, and Boston Scientific (BSX) $40.06 +1.82.

AVY

Avery Dennison

$127.53

8.97 (7.57%)

IVZ

Invesco

$16.66

0.63 (3.93%)

TMO

Thermo Fisher

$291.72

10.83 (3.86%)

ALXN

Alexion

$105.25

6.03 (6.08%)

BSX

Boston Scientific

$40.49

2.28 (5.97%)

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 04

    Nov

  • 06

    Nov

  • 13

    Nov

  • 02

    Dec

  • 07

    Dec

AVY Avery Dennison
$127.53

8.97 (7.57%)

09/23/19
KEYB
09/23/19
NO CHANGE
KEYB
Sector Weight
Avery Dennison continues to face economic, forex headwinds in Q3, says Keybanc
KeyBanc analyst Adam Josephson noted that he had previously reduced his 2019 estimates for Avery Dennison because of deteriorating global volume and demand trends, adding with just a week left in Q3 that the company faces those economic headwinds but also the impact of the continued strengthening of the U.S. dollar and recently imposed tariffs on most apparel imported from China. Falling input costs, specifically paper prices, could help, but he doesn't think they'll be enough to offset weak demand, unfavorable foreign exchange moves and potentially unfavorable tariff impacts. Josephson has a Sector Weight rating on Avery Dennison shares.
09/13/19
BOFA
09/13/19
UPGRADE
Target $130
BOFA
Buy
Avery Dennison upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst George Staphos upgraded Avery Dennison to Buy and raised his price target to $130 from $123, saying his prior concerns about its potential for decelerating revenues were priced into the stock after the company guided sluggish sales for the back half of the year. The analyst also expects Avery Dennison shares to benefit as investors rotate to cyclical names.
09/13/19
BOFA
09/13/19
UPGRADE
BOFA
Buy
Avery Dennison upgraded to Buy from Neutral at BofA/Merrill
08/16/19
BREN
08/16/19
INITIATION
Target $130
BREN
Buy
Avery Dennison initiated with a Buy at Berenberg (yesterday)
Berenberg analyst Paretosh Misra yesterday imitated coverage of Avery Dennison with a Buy rating and $130 price target. The analyst believes the company can deliver above-GDP growth and expand margins through 2021, leading to a "re-rating" of the shares.
IVZ Invesco
$16.66

0.63 (3.93%)

10/22/19
EVER
10/22/19
DOWNGRADE
EVER
Underperform
UBS initiative to pressure retail asset managers like Invesco, says Evercore ISI
Evercore ISI analyst Glenn Schorr downgraded Invesco (IVZ) to Underperform from In Line after UBS (UBS) announced a unified initiative between its wealth management and asset management businesses to potentially revolutionize how clients access separately managed accounts including significantly reduced SMA pricing. In a research note to investors, Schorr says he thinks this could be an accelerant of price compression in retail asset management products. Schorr also downgraded Waddell & Reed (WDR) to Underperform.
10/22/19
EVER
10/22/19
DOWNGRADE
EVER
Underperform
Invesco downgraded to Underperform from In Line at Evercore ISI
Evercore ISI analyst Glenn Schorr downgraded Invesco to Underperform from In Line.
10/10/19
WELS
10/10/19
NO CHANGE
Target $17
WELS
Market Perform
Invesco price target lowered to $17 from $23 at Wells Fargo
Wells Fargo analyst Christopher Harris lowered his price target for Invesco to $17 from $23 given more conservative forecasts for fee rates and fund flows. The analyst reiterates a Market Perform rating on the shares.
10/22/19
EVER
10/22/19
DOWNGRADE
EVER
Underperform
Waddell & Reed downgraded at Evercore ISI after UBS announces new initiative
Evercore ISI analyst Glenn Schorr downgraded Waddell & Reed (WDR) to Underperform from In Line after UBS (UBS) announced a unified initiative between its wealth management and asset management businesses to potentially revolutionize how clients access separately managed accounts including significantly reduced SMA pricing. In a research note to investors, Schorr says he thinks this could be an accelerant of price compression in retail asset management products. Schorr also downgraded Invesco (IVZ) to Underperform.
TMO Thermo Fisher
$291.72

10.83 (3.86%)

07/16/19
NEED
07/16/19
DOWNGRADE
Target $315
NEED
Buy
Thermo Fisher downgraded to Buy from Strong Buy at Needham
Needham analyst Stephen Unger downgraded Thermo Fisher to Buy from Strong Buy with an unchanged price target of $315.
07/16/19
07/16/19
DOWNGRADE
Target $315

Buy
Thermo Fisher downgraded to Buy at Needham on valuation, slower growth
As previously reported, Needham analyst Stephen Unger downgraded Thermo Fisher to Buy from Strong Buy with an unchanged price target of $315. The analyst cites the "meaningful valuation improvement" of 32% for the stock over the past six months vs. the 20% advance for S&P500 along with his expectation of decelerating near-term organic revenue growth from the 7.2% reported in Q1 given the slower global business investment spending environment.
10/16/19
CLVD
10/16/19
NO CHANGE
CLVD
Neutral
Thermo Fisher growth rate has moderated from first half, says Cleveland Research
Cleveland Research analyst Steve Willoughby said his recent checks suggest Thermo Fisher's growth rate has likely moderated from the first half of the year due to slower trends in Europe and China that are likely being somewhat offset by continued U.S. strength. He sees Q3 as "likely in-line" and thinks FY19 guidance appears realistic, though he said he is more concerned that the "end of year budget flush may be less impactful as compared to the past two years," Willoughby tells investors. He keeps a Neutral rating on Thermo Fisher shares.
10/08/19
CLVD
10/08/19
NO CHANGE
CLVD
Cleveland sees 'noticeable' slowdown in Life Science equipment demand
Cleveland Research analyst Steve Willoughby says his recent research suggests a "noticeable slowing" in Life Science equipment demand during Q3 in Europe, China, and parts of the U.S. The analyst who adjusted estimates for Thermo Fisher (TMO), Waters (WAT), Agilent (A), Mettler-Toledo (MTD), Avantor (AVTR), PerkinElmer (PKI) and Bruker (BRKR), believes a broader industry slowdown could impact industry multiples which he notes have expanded so far this year.
ALXN Alexion
$105.25

6.03 (6.08%)

10/18/19
LEER
10/18/19
DOWNGRADE
Target $6.3
LEER
Market Perform
Achillion acquisition by Alexion 'makes logical sense,' says SVB Leerink
SVB Leerink analyst Joseph Schwartz downgraded Achillion (ACHN) to Market Perform from Outperform with a price target of $6.30, up from $5. In a research note to investors, Schwartz says he thinks Alexion's (ALXN) proposed acquisition of Achillion makes logical sense as it brings highly complementary assets that can deliver a broader market opportunity together at a time "when the complement space could get more competitive." The analyst thinks the deal will close without any competing bids.
10/17/19
BOFA
10/17/19
INITIATION
Target $130
BOFA
Buy
Alexion reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Alexion Pharmaceuticals with a Buy rating and $130 price target. "Noise" around complement competition has overshadowed Alexion's "strong" fundamentals, driven by its Soliris/Ultomiris franchise, Meacham tells investors in a research note. The analyst likes the stock's risk/reward profile given the company's "differentiated" growth and "discounted" valuation.
10/16/19
PIPR
10/16/19
NO CHANGE
Target $180
PIPR
Overweight
Piper likes Alexion acquisition of Achillion, remains buyer of shares
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Alexion Pharmaceuticals (ALXN) with a $180 price target after this morning's announced acquisition of Achillion Pharmaceuticals (ACHN). The deal brings in danicopan, an oral Factor D inhibitor, as combination therapy with Soliris for the treatment of paroxysmal nocturnal hemoglobinuria and monotherapy for C3 glomerulopathy, and ACH-5228, a second generation oral Factor D inhibitor, expected to enter the clinic early next year, Raymond tells investors in a research note. The analyst likes the deal. Achillion has already shown proof of concept in PNH and strategically the company adds to the diversification of Alexion's pipeline, says Raymond. The analyst remains a buyer of Alexion shares.
10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
BSX Boston Scientific
$40.49

2.28 (5.97%)

09/20/19
COWN
09/20/19
NO CHANGE
Target $47
COWN
Outperform
Boston Scientific setting up well for better second half, says Cowen
Cowen analyst Joshua Jennings said Boston Scientific is setting up for a batter second half to the year as the company has a steady flow of product launches scheduled for the second half and should also experience momentum in its core businesses over that interval. In addition, there is one more selling day in the second half versus one less in the first. Jennings reiterated his Outperform rating and $47 price target on Boston Scientific shares.
09/05/19
09/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. General Electric (GE) initiated with an Equal Weight at Morgan Stanley. 2. Organigram (OGI) initiated with a Perform at Oppenheimer. 3. Wingstop (WING) initiated with a Market Perform at Raymond James. 4. Boston Scientific (BSX) reinstated with an Overweight at JPMorgan. 5. Cubic (CUB) initiated with a Hold at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/05/19
JPMS
09/05/19
INITIATION
Target $50
JPMS
Overweight
Boston Scientific reinstated with an Overweight at JPMorgan
JPMorgan analyst Robbie Marcus reinstated coverage of Boston Scientific with an Overweight rating and $50 price target following a period of restriction. The analyst continues to see the company as a "best-in-class Large-Cap MedTech asset," with "many shots on goal" to support a multi-year premium organic sales growth trajectory of 7%-10% through 2023.
09/03/19
LEHM
09/03/19
INITIATION
Target $48
LEHM
Overweight
Boston Scientific reinstated with an Overweight at Barclays
Barclays analyst Kristen Stewart reinstated coverage of Boston Scientific with an Overweight rating and $48 price target. With multiple new products across all of its business units, the company is well positioned to sustain high-single digit organic sales growth for the foreseeable future, Stewart tells investors in a research note. She believes the consensus view on the stock "is the right view."

TODAY'S FREE FLY STORIES

QGEN

Qiagen

$37.50

0.195 (0.52%)

15:22
11/15/19
11/15
15:22
11/15/19
15:22
Hot Stocks
Breaking Hot Stocks news story on Qiagen »

Qiagen decides to enter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

15:20
11/15/19
11/15
15:20
11/15/19
15:20
General news
Treasury Market Summary »

Treasury Market Summary:…

TMO

Thermo Fisher

$306.76

5.94 (1.97%)

, QGEN

Qiagen

$37.51

0.205 (0.55%)

15:18
11/15/19
11/15
15:18
11/15/19
15:18
Hot Stocks
Breaking Hot Stocks news story on Thermo Fisher, Qiagen »

Thermo Fisher up 2% to…

TMO

Thermo Fisher

$306.76

5.94 (1.97%)

QGEN

Qiagen

$37.51

0.205 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 07

    Dec

NVS

Novartis

$90.12

0.6 (0.67%)

15:18
11/15/19
11/15
15:18
11/15/19
15:18
Hot Stocks
Novartis confirms Adakveo approved by FDA »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AGTC

Applied Genetic

$2.76

-0.125 (-4.33%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Conference/Events
Applied Genetic management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 04

    Dec

QGEN

Qiagen

$37.48

0.175 (0.47%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Hot Stocks
Breaking Hot Stocks news story on Qiagen »

Qiagen trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
11/15/19
11/15
15:16
11/15/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$133.46

2.48 (1.89%)

15:00
11/15/19
11/15
15:00
11/15/19
15:00
Periodicals
Oklahoma judge cuts J&J payment due in opioid case to $465M, Reuters reports »

An Oklahoma judge has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

EA

Electronic Arts

$97.88

0.34 (0.35%)

14:59
11/15/19
11/15
14:59
11/15/19
14:59
Periodicals
EA, BioWare planning complete revamp of 'Anthem,' Kotaku says »

Video game developer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

F

Ford

$8.95

0.15 (1.70%)

, GM

General Motors

$36.92

0.12 (0.33%)

14:56
11/15/19
11/15
14:56
11/15/19
14:56
Periodicals
States sue EPA for right for stricter emission regulations, Washington Post says »

California, along with 23…

F

Ford

$8.95

0.15 (1.70%)

GM

General Motors

$36.92

0.12 (0.33%)

HMC

Honda

$29.01

0.175 (0.61%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$144.15

1.02 (0.71%)

TSLA

Tesla

$350.80

1.29 (0.37%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.03

0.05 (0.31%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 09

    Dec

  • 04

    Feb

MDLZ

Mondelez

$52.71

-0.19 (-0.36%)

14:52
11/15/19
11/15
14:52
11/15/19
14:52
Hot Stocks
Mondelez recalls Cheese Nips in U.S. due to potential presence of plastic pieces »

Mondelez Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COLM

Columbia Sportswear

$93.21

-1.28 (-1.35%)

14:50
11/15/19
11/15
14:50
11/15/19
14:50
Conference/Events
Columbia Sportswear participates in a conference call with Wedbush »

Footwear & Apparel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

14:47
11/15/19
11/15
14:47
11/15/19
14:47
Conference/Events
Wedbush hardware/component analyst to hold an analyst/industry conference call »

Hardware & Component…

NVS

Novartis

$89.84

0.32 (0.36%)

14:43
11/15/19
11/15
14:43
11/15/19
14:43
Hot Stocks
Novartis receives FDA approval for BLA for Adakveo injection »

The FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ALNA

Allena Pharmaceuticals

$1.61

-0.03 (-1.83%)

14:39
11/15/19
11/15
14:39
11/15/19
14:39
Conference/Events
Wedbush emerging pharma analyst to hold an analyst/industry conference call »

Emerging Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$138.00

3.53 (2.63%)

, CYH

Community Health

$2.95

0.075 (2.61%)

14:38
11/15/19
11/15
14:38
11/15/19
14:38
Hot Stocks
Hospital stocks up after Trump reveals healthcare price transparency proposal »

Shares of several…

HCA

HCA Healthcare

$138.00

3.53 (2.63%)

CYH

Community Health

$2.95

0.075 (2.61%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$142.53

1.36 (0.96%)

THC

Tenet

$29.91

0.44 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$23.69

2.2 (10.24%)

14:28
11/15/19
11/15
14:28
11/15/19
14:28
Recommendations
Amarin analyst commentary  »

Amarin price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

VIA

Viacom

$26.63

1.32 (5.22%)

, VIAB

Viacom

$23.20

0.72 (3.20%)

14:25
11/15/19
11/15
14:25
11/15/19
14:25
On The Fly
Box Office Battle: 'Ford v Ferrari' seen topping 'Charlie's Angels' this weekend »

Welcome to "Box Office…

VIA

Viacom

$26.63

1.32 (5.22%)

VIAB

Viacom

$23.20

0.72 (3.20%)

FOX

Fox Corp.

$33.85

0.39 (1.17%)

FOXA

Fox Corp.

$34.51

0.29 (0.85%)

T

AT&T

$39.28

0.315 (0.81%)

DIS

Disney

$144.95

-2.24 (-1.52%)

CMCSA

Comcast

$44.61

-0.86 (-1.89%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$9.76

0.41 (4.39%)

LGF.B

Lionsgate

$9.15

0.43 (4.93%)

SNE

Sony

$62.10

0.3 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

AZN

AstraZeneca

$47.18

-0.19 (-0.40%)

14:25
11/15/19
11/15
14:25
11/15/19
14:25
Options
AstraZeneca call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

14:25
11/15/19
11/15
14:25
11/15/19
14:25
General news
Treasury Action: Treasuries remain slightly weaker »

Treasury Action:…

GOOG

Alphabet

$1,328.60

16.41 (1.25%)

, GOOGL

Alphabet Class A

$1,327.62

17.83 (1.36%)

14:20
11/15/19
11/15
14:20
11/15/19
14:20
Hot Stocks
Supreme Court to consider Google appeal of Oracle copyright case »

The U.S. Supreme Court…

GOOG

Alphabet

$1,328.60

16.41 (1.25%)

GOOGL

Alphabet Class A

$1,327.62

17.83 (1.36%)

ORCL

Oracle

$56.42

0.32 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/15/19
11/15
14:17
11/15/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,748.38

-6.33 (-0.36%)

14:16
11/15/19
11/15
14:16
11/15/19
14:16
Periodicals
John Lynch leaving Amazon Studios, Variety reports »

Amazon Studios head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/15/19
11/15
14:16
11/15/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.